Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice

F. Zheng, Y. J. Zeng, A. R. Plati, Sharon Elliot, M. Berho, M. Potier, L. J. Striker, G. E. Striker

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The accumulation of advanced glycation end products (AGE) is a key factor in diabetic nephropathy (DN). Pyridoxamine inhibits AGE formation and protects against type I DN. Herein we tested: (1) whether C57BL6 db/db mice as a model of established type II DN resembled patients treated with drugs which inhibit angiotensin II action; (2) whether pyridoxamine was effective as a single therapy; and (3) whether pyridoxamine would add to the benefit of angiotensin-converting enzyme inhibition (ACEi) by enalapril. In first set of experiments mice were treated with ACEi (benazepril) and an angiotensin II receptor blocker (valsartan) combination for 16 weeks after the onset of diabetes. In second group, mice with established DN were treated with pyridoxamine for 8 weeks. In a third set, mice with established DN were treated with pyridoxamine and enalapril combination for 16 weeks. Benazepril and valsartan combination partially prevented the development and progression of DN. Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions. The combination of pyridoxamine with enalapril reduced both mortality and the progression of DN. In conclusion, (1) C57 BL6 db/db mice are a model of progressive type II DN; (2) The combination of pyridoxamine with enalapril decreased progression of type 2 DN and overall mortality. Thus, pyridoxamine could be a valuable adjunct to the current treatment of established type II DN.

Original languageEnglish
Pages (from-to)507-514
Number of pages8
JournalKidney International
Volume70
Issue number3
DOIs
StatePublished - Aug 21 2006

Fingerprint

Pyridoxamine
Advanced Glycosylation End Products
Diabetic Nephropathies
Peptidyl-Dipeptidase A
Enalapril
Valsartan
Albuminuria
Mortality
Angiotensin Receptor Antagonists
Therapeutics
Angiotensin II

Keywords

  • Advanced glycation end products
  • AGE inhibition
  • Angiotensin-converting enzyme inhibitor
  • Diabetic nephropathy
  • Glomerular hypertrophy
  • Type II diabetes mellitus

ASJC Scopus subject areas

  • Nephrology

Cite this

Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. / Zheng, F.; Zeng, Y. J.; Plati, A. R.; Elliot, Sharon; Berho, M.; Potier, M.; Striker, L. J.; Striker, G. E.

In: Kidney International, Vol. 70, No. 3, 21.08.2006, p. 507-514.

Research output: Contribution to journalArticle

Zheng, F. ; Zeng, Y. J. ; Plati, A. R. ; Elliot, Sharon ; Berho, M. ; Potier, M. ; Striker, L. J. ; Striker, G. E. / Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. In: Kidney International. 2006 ; Vol. 70, No. 3. pp. 507-514.
@article{d52913e3e65d48aa88dfc316fe3d59ab,
title = "Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice",
abstract = "The accumulation of advanced glycation end products (AGE) is a key factor in diabetic nephropathy (DN). Pyridoxamine inhibits AGE formation and protects against type I DN. Herein we tested: (1) whether C57BL6 db/db mice as a model of established type II DN resembled patients treated with drugs which inhibit angiotensin II action; (2) whether pyridoxamine was effective as a single therapy; and (3) whether pyridoxamine would add to the benefit of angiotensin-converting enzyme inhibition (ACEi) by enalapril. In first set of experiments mice were treated with ACEi (benazepril) and an angiotensin II receptor blocker (valsartan) combination for 16 weeks after the onset of diabetes. In second group, mice with established DN were treated with pyridoxamine for 8 weeks. In a third set, mice with established DN were treated with pyridoxamine and enalapril combination for 16 weeks. Benazepril and valsartan combination partially prevented the development and progression of DN. Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions. The combination of pyridoxamine with enalapril reduced both mortality and the progression of DN. In conclusion, (1) C57 BL6 db/db mice are a model of progressive type II DN; (2) The combination of pyridoxamine with enalapril decreased progression of type 2 DN and overall mortality. Thus, pyridoxamine could be a valuable adjunct to the current treatment of established type II DN.",
keywords = "Advanced glycation end products, AGE inhibition, Angiotensin-converting enzyme inhibitor, Diabetic nephropathy, Glomerular hypertrophy, Type II diabetes mellitus",
author = "F. Zheng and Zeng, {Y. J.} and Plati, {A. R.} and Sharon Elliot and M. Berho and M. Potier and Striker, {L. J.} and Striker, {G. E.}",
year = "2006",
month = "8",
day = "21",
doi = "10.1038/sj.ki.5001578",
language = "English",
volume = "70",
pages = "507--514",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice

AU - Zheng, F.

AU - Zeng, Y. J.

AU - Plati, A. R.

AU - Elliot, Sharon

AU - Berho, M.

AU - Potier, M.

AU - Striker, L. J.

AU - Striker, G. E.

PY - 2006/8/21

Y1 - 2006/8/21

N2 - The accumulation of advanced glycation end products (AGE) is a key factor in diabetic nephropathy (DN). Pyridoxamine inhibits AGE formation and protects against type I DN. Herein we tested: (1) whether C57BL6 db/db mice as a model of established type II DN resembled patients treated with drugs which inhibit angiotensin II action; (2) whether pyridoxamine was effective as a single therapy; and (3) whether pyridoxamine would add to the benefit of angiotensin-converting enzyme inhibition (ACEi) by enalapril. In first set of experiments mice were treated with ACEi (benazepril) and an angiotensin II receptor blocker (valsartan) combination for 16 weeks after the onset of diabetes. In second group, mice with established DN were treated with pyridoxamine for 8 weeks. In a third set, mice with established DN were treated with pyridoxamine and enalapril combination for 16 weeks. Benazepril and valsartan combination partially prevented the development and progression of DN. Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions. The combination of pyridoxamine with enalapril reduced both mortality and the progression of DN. In conclusion, (1) C57 BL6 db/db mice are a model of progressive type II DN; (2) The combination of pyridoxamine with enalapril decreased progression of type 2 DN and overall mortality. Thus, pyridoxamine could be a valuable adjunct to the current treatment of established type II DN.

AB - The accumulation of advanced glycation end products (AGE) is a key factor in diabetic nephropathy (DN). Pyridoxamine inhibits AGE formation and protects against type I DN. Herein we tested: (1) whether C57BL6 db/db mice as a model of established type II DN resembled patients treated with drugs which inhibit angiotensin II action; (2) whether pyridoxamine was effective as a single therapy; and (3) whether pyridoxamine would add to the benefit of angiotensin-converting enzyme inhibition (ACEi) by enalapril. In first set of experiments mice were treated with ACEi (benazepril) and an angiotensin II receptor blocker (valsartan) combination for 16 weeks after the onset of diabetes. In second group, mice with established DN were treated with pyridoxamine for 8 weeks. In a third set, mice with established DN were treated with pyridoxamine and enalapril combination for 16 weeks. Benazepril and valsartan combination partially prevented the development and progression of DN. Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions. The combination of pyridoxamine with enalapril reduced both mortality and the progression of DN. In conclusion, (1) C57 BL6 db/db mice are a model of progressive type II DN; (2) The combination of pyridoxamine with enalapril decreased progression of type 2 DN and overall mortality. Thus, pyridoxamine could be a valuable adjunct to the current treatment of established type II DN.

KW - Advanced glycation end products

KW - AGE inhibition

KW - Angiotensin-converting enzyme inhibitor

KW - Diabetic nephropathy

KW - Glomerular hypertrophy

KW - Type II diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=33746520563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746520563&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5001578

DO - 10.1038/sj.ki.5001578

M3 - Article

C2 - 16775596

AN - SCOPUS:33746520563

VL - 70

SP - 507

EP - 514

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -